Table 3.
Association of genetic polymorphism with warfarin dose requirements in Egyptians
| Gene | Variant | Genotype | Frequency (n = 207) | Mean ± SD warfarin dose (mg/week) | P valuea |
|---|---|---|---|---|---|
| CYP2C9 | *2*3*4*5*8 | *1/*1 | 122 (62.56%) | 40.3 ± 19.5 | 0.0028 |
| *1/*2 | 34 (17.44%) | 35.0 ± 16.9 | |||
| *1/*3 | 23 (11.79%) | 26.6 ± 10.4 | |||
| *1/*4 | 1 (0.51%) | 35 | |||
| *1/*5 | 2 (1.03%) | 28.0 ± 10 | |||
| *1/*8 | 3 (1.45%) | 39.7 ± 10.7 | |||
| *2/*2 | 2 (1.03%) | 29.8 ± 2.5 | |||
| *2/*3 | 8 (4.10%) | 32.4 ± 17.2 | |||
| *3/*3 | 2 (1.03%) | 33.3 ± 17.3 | |||
| *5/*5 | 1 (0.51%) | 31.5 | |||
| VKORC1 | 3673G > A | GG | 50 (25.51%) | 43.4 ± 21.6 | < 0.0001 |
| GA | 111 (56.63%) | 38.1 ± 16.4 | |||
| AA | 35 (17.86%) | 25.6 ± 12.3 | |||
| CYP4F2 | V433M | CC | 68 (35.42%) | 35.2 ± 16.1 | 0.31 |
| CT | 87 (45.31%) | 37.3 ± 18.7 | |||
| TT | 37 (19.27%) | 41.1 ± 20.9 | |||
| APOE | ε2/ε2 | 3 (1.54%) | 21.0 ± 3.5 | ε2 haplotype 0, 1, 2: P = 0.08 | |
| ε2/ε3 | 20 (10.26%) | 31.0 ± 15.1 | |||
| ε2/ε4 | 3 (1.54%) | 49.0 ± 18.2 | |||
| ε3/ε3 | 146 (74.87%) | 38.2 ± 17.9 | |||
| ε3/ε4 | 23 (11.79%) | 35.6 ± 22.0 | |||
| CALU | rs339097 | TT | 186 (95.38%) | 36.5 ± 17.9 | 0.04 |
| CT | 9 (4.62%) | 50.6 ± 21.3 |
SD, standard deviation.
a
These P values were generated using nonparametric methods (Kruskal–Wallis or Wilcoxon Rank-sum test as appropriate).